CMV pp65 TCR-modified T cells

CMV pp65 TCR-modified T cells is an adoptive cell therapy consisting of T cells genetically engineered, typically via lentiviral transduction, to express a T-cell receptor (TCR) specific for the cytomegalovirus (CMV) pp65 antigen (also known as UL83). This therapy is designed to recognize and eliminate CMV-infected cells by targeting pp65 epitopes presented by HLA class I molecules. It is primarily investigated for the treatment or prevention of CMV infection and reactivation in immunocompromised patients, such as those undergoing allogeneic hematopoietic stem cell transplantation (HSCT), where natural CMV-specific T-cell immunity is often deficient. The therapy targets multiple pp65 epitopes across major HLA-A alleles, enabling the engineered T cells to recognize and kill CMV-infected cells.

Other names

CMV pp65-specific TCR-engineered T cellsCMVpp65-specific-modified T cellsCMVpp-65-specific-modified T cellsCMVpp 65-specific-modified T cells